Stereotaxis, Inc. (STXS) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, Stereotaxis reported revenue of $32.4M, up 20.3% from $26.9M the year before. Net income was -$21.6M (a -66.8% net margin), or -$0.25 per diluted share. Gross margin was 52.7% and operating margin was -68.3%. Operating activities generated -$13.7M of cash, leaving -$13.8M of free cash flow. At fiscal year end, Stereotaxis held $52.3M in total assets against $33.5M in total liabilities, including $13.4M of cash and equivalents.
Open the full interactive Stereotaxis financials → Quarterly statements, key ratios, valuation history and price charts.
Stereotaxis Key Stats
| Share Price | $1.06 |
|---|---|
| Market Cap | $106.0M |
| Revenue YoY Growth | +20.3% |
| 52-Week Range | $1.06 – $3.15 |
| Shares Outstanding | 100.0 million (basic, 2026 Q2) |
Stereotaxis Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $26.6M | $35.0M | $28.1M | $26.8M | $26.9M | $32.4M |
| Gross Profit | $19.0M | $23.2M | $18.5M | $14.9M | $14.6M | $17.1M |
| Operating Income | -$6.7M | -$12.9M | -$18.8M | -$21.8M | -$24.7M | -$22.1M |
| Pre-Tax Income | -$6.6M | -$10.7M | -$18.3M | -$20.7M | -$24.0M | -$21.6M |
| Net Income | -$6.6M | -$10.7M | -$18.3M | -$20.7M | -$24.0M | -$21.6M |
| Diluted EPS | -$0.11 | -$0.16 | -$0.26 | -$0.27 | -$0.30 | -$0.25 |
Stereotaxis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.5M | $8.6M | $6.3M | $7.7M |
| Net Income | -$6.5M | -$5.5M | -$5.9M | -$4.5M |
| Diluted EPS | -$0.07 | -$0.06 | -$0.06 | -$0.05 |
Stereotaxis Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $43.9M | $38.7M | $8.6M | $19.8M | $12.2M | $13.4M |
| Current Assets | $52.7M | $51.4M | $43.2M | $33.3M | $26.4M | $33.8M |
| Total Assets | $55.5M | $61.0M | $53.4M | $41.9M | $46.7M | $52.3M |
| Current Liabilities | $13.6M | $13.3M | $14.3M | $13.2M | $21.6M | $22.4M |
| Total Long-Term Debt | $973,252 | — | — | — | — | — |
| Total Liabilities | $15.2M | $21.6M | $21.5M | $20.0M | $35.3M | $33.5M |
| Shareholders' Equity | $34.6M | $33.8M | $26.3M | $16.3M | $6.1M | $13.5M |
Stereotaxis Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.5M | -$2.9M | -$8.4M | -$9.1M | -$8.5M | -$13.7M |
| Cash From Investing | -$70,896 | -$1.4M | -$22.1M | $19.8M | $74,000 | -$93,000 |
| Cash From Financing | $17.3M | $547,411 | $220,000 | $81,000 | $297,000 | $14.8M |
| Free Cash Flow | -$3.6M | -$4.3M | -$10.8M | -$9.5M | -$8.5M | -$13.8M |
Figures from Stereotaxis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Stereotaxis financials page for every line item.
Stereotaxis Company Profile
| Ticker | STXS |
|---|---|
| Exchange | NYSE |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | St.Louis, Missouri |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001289340 |
Frequently Asked Questions
What was Stereotaxis' revenue in fiscal 2025?
Stereotaxis (STXS) reported revenue of $32.4M for fiscal 2025.
What is Stereotaxis' annual revenue history?
Stereotaxis' annual revenue by fiscal year: 2020: $26.6M; 2021: $35.0M; 2022: $28.1M; 2023: $26.8M; 2024: $26.9M; 2025: $32.4M.
What was Stereotaxis' net income in fiscal 2025?
Stereotaxis reported net income of -$21.6M for fiscal 2025.
What was Stereotaxis' earnings per share (EPS) in fiscal 2025?
Stereotaxis' diluted EPS was -$0.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Stereotaxis generate in fiscal 2025?
Stereotaxis generated -$13.8M of free cash flow in fiscal 2025.
What was Stereotaxis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Stereotaxis reported revenue of $7.7M.
How many shares of Stereotaxis are outstanding?
Stereotaxis reported a weighted average of 100.0 million basic shares outstanding in 2026 Q2.
What is Stereotaxis' market cap?
Based on its latest closing price, Stereotaxis (STXS) has a market capitalization of about $106.0M.
When does Stereotaxis' fiscal year end?
Stereotaxis' fiscal year end, as registered with the SEC, is December 31.
Where is Stereotaxis headquartered?
Stereotaxis lists its business address in St.Louis, Missouri in its SEC filings.